Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Sarcoma

This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
Sarcoma
III
Keedy, Vicki
NCT03016819
VICCSAR1796

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: